Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not reported in the declared source.
Participants or experimental system
Blood samples from healthy donors were obtained from the Fifth Medical Center of Chinese PLA General Hospital (Beijing, China).
Study scale
Not reported in the declared source.
Intervention or exposure
The Fmoc-protected resin and monomers are first treated with a basic solvent (piperidine) to remove the amino protecting groups.
Comparator
After incubation at 37 °C for 30 min, the samples were centrifuged, and the absorbance of the supernatant was measured at 450 nm using a multi-well microplate reader (SpectraMax M5; Molecular Devices, Sunnyvale, CA, USA) and compared with the 100% haemolysis caused by 0.1% Triton X-100.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Cell viability was measured using the standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Supragingival plaque was collected from five healthy participants and supragingival and subgingival plaque from five with gingivitis.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not reported in the declared source.
Outcomes examined
The degree of erythema, skin thickening, and scaling on the affected area was quantified using the 4-point scale psoriasis area and severity index (PASI) (0=none; 1=slight; 2=moderate; 3=marked; 4=very marked).
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Study scale: The BAL fluid samples from LPS-exposed airways were pooled together (material from n = 10 healthy volunteers, total of 14 mL), cleared from debris by centrifugation (5,000 rpm for 15 min) and reconstituted in 0.1% TFA.
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The aim of this study was to detect citrullinated LL-37 in human bronchoalveolar lavage (BAL) fluid and to determine antibacterial and biophysical properties of citrullinated LL-37.
Study design
Not reported in the declared source.
Participants or experimental system
BAL fluid was obtained from healthy human volunteers after intra-bronchial exposure to lipopolysaccharide.
Study scale
The BAL fluid samples from LPS-exposed airways were pooled together (material from n = 10 healthy volunteers, total of 14 mL), cleared from debris by centrifugation (5,000 rpm for 15 min) and reconstituted in 0.1% TFA.
Intervention or exposure
Healthy human volunteers were exposed to LPS and after 24 h, BAL fluid samples were collected.
Comparator
In brief, healthy volunteers were exposed via bronchoscopy to vehicle, i.e., 10 mL of 0.9% PBS in one lung and to LPS (4 ng/kg) from Escherichia coli (E. coli) 0113:H10 (Rockville, MD, USA), diluted in PBS, in the other lung.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Thus it cannot be excluded that the initial screen revealed additional forms of citrullinated LL-37 that we could not distinguish with the LC-MS/MS analysis, due to analytical constraints.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Study scale: Fluorescence intensities were measured after a 1-h treatment with 10 μg/mL H2A, 1 μM LL-37, or both H2A and LL-37 (n = 6 for each condition); or with 1 μg/mL PMB or H2A and PMB (n = 3 for each condition).
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
We hypothesized that decreasing Mg2+ concentrations would destabilize the bacterial membrane, increasing H2A entry and bactericidal activity.
Study design
Not reported in the declared source.
Participants or experimental system
All the cells were harvested at mid-exponential growth phase and were cultured in buffered medium, which minimizes potential changes in pH.
Study scale
Fluorescence intensities were measured after a 1-h treatment with 10 μg/mL H2A, 1 μM LL-37, or both H2A and LL-37 (n = 6 for each condition); or with 1 μg/mL PMB or H2A and PMB (n = 3 for each condition).
Intervention or exposure
Bacteria were treated for 1 h before plating on non-selective LB agar plates.
Comparator
Fluorescence was distributed uniformly in untreated cells, indicating a diffuse bacterial chromosome (Fig. 5d).
Outcomes examined
Fluorescence intensities in (b) were measured after a 1-h treatment with H2A alone or in combination with Cam, Kan, LL-37, or PMB.
Limitations and uncertainty
H2A-treated cells showed consistently low PI fluorescence across the recovery period, indicating the lack of membrane damage by H2A. These results suggest that bacteria can repair membrane pores induced by LL-37 but the presence of H2A inhibits repair of LL-37-induced pores.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Antibacterial activity measured using killing assays.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Study scale: We compared the expression levels of LL-37 in 45 adjacent normal lung tissues and 86 NSCLC tissues (i.e., 47 adenocarcinomas and 39 squamous cell carcinomas) through immunohistochemistry.
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
We subsequently investigated the levels of LL-37 in the sera of healthy donors and patients diagnosed with NSCLC.
Study design
The animal model of wild-type and Cramp knockout mice was employed to evaluate the tumorigenic effect of LL-37 in non-small cell lung cancer.
Participants or experimental system
The human lung adenocarcinoma cell line A549 and mouse LLC cells were obtained from the American Type Culture Collection, and cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, USA), supplemented with 10% fetal calf serum (Invitrogen, Carlsbad, USA), 100 U/ml penicillin, and 100 U/ml streptomycin (PAA Laboratories GmbH).
Study scale
We compared the expression levels of LL-37 in 45 adjacent normal lung tissues and 86 NSCLC tissues (i.e., 47 adenocarcinomas and 39 squamous cell carcinomas) through immunohistochemistry.
Intervention or exposure
Transfection complexes were removed after 2 h, and cells were stimulated with LL-37 in DMEM supplemented with 0.5% fetal calf serum for 24 h.
Comparator
Treatment with LL-37 caused accumulation of unphosphorylated β-catenin in the nuclei of A549 cells versus untreated cells, exhibiting diffuse localization with a small fraction of unphosphorylated β-catenin in the nuclei (Figure 4D).
Outcomes examined
Methods: The expression of LL-37 in the tissues and sera of patients with non-small cell lung cancer was determined through immunohistological, immunofluorescence analysis, and enzyme-linked immunosorbent assay.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Next, we asked whether increased expression of HIF-1α was reflected by a functional activation of this transcription factor.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
The trans-epithelial electrical resistance (TEER) of five wells per treatment condition was evaluated at day 7 post-infection, and is presented as median Ω × cm2 ± SEM of five individual wells per treatment condition, with the range of TEER measurements indicated in parentheses.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not reported in the declared source.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
The ability of LL-37 present in treated and untreated CF sputum to inhibit LPS-induced IL-8 production by THP-1 monocytic cells was analysed by a modification of the above LPS-binding ELISA protocol.
Outcomes examined
GAG levels were measured using the Blyscan Blue sGAG assay as directed by the manufacturer (Biocolour Ltd., Co Antrim, Northern Ireland).
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
To understand the mechanism underlying the more efficient infection by curliated bacteria, we specifically investigated the antimicrobial activity of bladder and renal epithelial cells on adhered bacteria.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked